Eric B. Kmiec, Ph.D.
Widely recognized as a pioneer in the breakthrough technology, Gene Editing, Dr. Eric Kmiec is the Founder and Director of the Gene Editing Institute at the Helen F Graham Cancer Center & Research Institute, Christiana Healthcare System with faculty appointments at the University of Delaware, the Wistar Institute and Georgetown University Medical School. His laboratory has been supported by the National Institute of Health in the form of R01 and R21 grants respectively for over 22 years. He has also received funding from the High Q Foundation, Hereditary Disease Foundation, the American Cancer Society, the March of Dimes, Pfizer, Bio-Rad, Tapestry Biotherapeutics and a variety of biotechnology companies. He serves on the editorial boards of many journals, has authored over 140 peer-reviewed journal publications and edited several books on gene therapy. Dr. Kmiec has 15 issued patents with 30 applications and founded two biotechnology companies (Kimeragen , now Cibus in San Diego California, and Orphagenix LLC). He is currently a Senior Consultant and member of the Scientific Advisory Board of the gene editing company, ETAGEN located in Cambridge, Massachusetts. Over the course of his 20+ year career, Dr. Kmiec has been the primary mentor for 13 (graduated) doctoral students and many postdoctoral fellows. He has received numerous research and community service medals and awards, including, most recently, the Genome Quebec and Genome Canada Lectureship and the William F. Proudford Sickle Cell Anemia Research Award. From 1999-2008, Dr. Kmiec was a full, tenured Professor of Biology at the University of Delaware and Director of the Applied Genomics Laboratory at the Delaware Biotechnology Institute.